TR199902071T2 - Heterocyclic compounds and their use in inhibition of β-amylioid peptide - Google Patents

Heterocyclic compounds and their use in inhibition of β-amylioid peptide

Info

Publication number
TR199902071T2
TR199902071T2 TR1999/02071T TR9902071T TR199902071T2 TR 199902071 T2 TR199902071 T2 TR 199902071T2 TR 1999/02071 T TR1999/02071 T TR 1999/02071T TR 9902071 T TR9902071 T TR 9902071T TR 199902071 T2 TR199902071 T2 TR 199902071T2
Authority
TR
Turkey
Prior art keywords
peptide
amylioid
inhibition
heterocyclic compounds
alzheimer
Prior art date
Application number
TR1999/02071T
Other languages
Turkish (tr)
Inventor
D. Thorsett Eugene
J. Porter Warren
S. Nissen Jeffrey
H. Latimer Lee
E. Audia James
J. Droste James
Original Assignee
Elan Pharmaceuticals, Inc
Eli Lilly & Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharmaceuticals, Inc, Eli Lilly & Company filed Critical Elan Pharmaceuticals, Inc
Publication of TR199902071T2 publication Critical patent/TR199902071T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/10—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Abstract

-Amiloid peptidinin salinmasini ve/veya sentezini inhibe eden ve dolayisiyla Alzheimer hastaliginin tedavisinde kullanilabilen bilesikler açiklanmaktadir. Ayrica -Amiloid peptidinin salinmasini ve/veya sentezini inhibe eden bir bilesik içeren farmasötik bilesimler ve Alzheimer hastaliginin böyle bilesimlerle profilaktik ve terappötik tedavisi için yöntemler açiklanmaktadir. Compounds are described which inhibit the release and / or synthesis of the amyloid peptide and thus can be used in the treatment of Alzheimer's disease. Also disclosed are pharmaceutical compositions containing a compound that inhibits the release and / or synthesis of the amyloid peptide, and methods for prophylactic and therapeutic treatment of Alzheimer's disease with such compositions.

TR1999/02071T 1997-02-28 1998-02-27 Heterocyclic compounds and their use in inhibition of β-amylioid peptide TR199902071T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80826397A 1997-02-28 1997-02-28

Publications (1)

Publication Number Publication Date
TR199902071T2 true TR199902071T2 (en) 2000-01-21

Family

ID=25198310

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/02071T TR199902071T2 (en) 1997-02-28 1998-02-27 Heterocyclic compounds and their use in inhibition of β-amylioid peptide

Country Status (22)

Country Link
EP (1) EP0968198A1 (en)
JP (1) JP2001513107A (en)
KR (1) KR20000075767A (en)
CN (1) CN1253554A (en)
AR (1) AR011164A1 (en)
AU (1) AU6662298A (en)
BR (1) BR9807876A (en)
CA (1) CA2278674A1 (en)
CO (1) CO4920244A1 (en)
EA (1) EA199900778A1 (en)
HR (1) HRP980093A2 (en)
HU (1) HUP0001293A3 (en)
ID (1) ID22873A (en)
IL (1) IL130851A0 (en)
NO (1) NO994016L (en)
NZ (1) NZ336613A (en)
PE (1) PE59399A1 (en)
PL (1) PL335424A1 (en)
TR (1) TR199902071T2 (en)
WO (1) WO1998038177A1 (en)
YU (1) YU7998A (en)
ZA (1) ZA981627B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
WO1999032453A1 (en) * 1997-12-22 1999-07-01 Elan Pharmaceuticals, Inc. POLYCYCLIC α-AMINO-⊂-CAPROLACTAMS AND RELATED COMPOUNDS
US6569851B1 (en) 1998-06-22 2003-05-27 Elan Pharmaceutials, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6774125B2 (en) 1998-06-22 2004-08-10 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
JP2002518481A (en) * 1998-06-22 2002-06-25 エラン ファーマシューティカルズ，インコーポレイテッド Compounds for inhibiting the release of β-amyloid peptide and / or its synthesis
US6528505B1 (en) 1998-06-22 2003-03-04 Elan Pharmaceuticals, Inc. Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6552013B1 (en) 1998-06-22 2003-04-22 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6737038B1 (en) 1998-11-12 2004-05-18 Bristol-Myers Squibb Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
EP1159273A1 (en) 1999-03-02 2001-12-05 Boehringer Ingelheim Pharmaceuticals Inc. Compounds useful as reversible inhibitors of cathepsin s
US7160880B1 (en) * 1999-05-14 2007-01-09 Cenes Limited Short-acting benzodiazepines
GB9911803D0 (en) * 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
JP2003506440A (en) * 1999-08-05 2003-02-18 プレサイエント ニューロファーマ インコーポレイテッド 1,4-Diazepine derivatives for the treatment of diseases associated with the central nervous system
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
US6878363B2 (en) 2000-05-17 2005-04-12 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
AU783857B2 (en) 2000-06-01 2005-12-15 Bristol-Myers Squibb Pharma Company Lactams substituted by cyclic succinates as inhibitors of a beta protein production
DE10029077A1 (en) * 2000-06-13 2001-12-20 Bayer Ag New heterocyclic-substituted thiazole derivatives, useful as total or selective herbicides, insecticides, acaricides, nematocides, ectoparasiticides or antifouling agents
US6432944B1 (en) 2000-07-06 2002-08-13 Bristol-Myers Squibb Company Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives
FR2840899B1 (en) * 2002-06-12 2005-02-25 Sanofi Synthelabo ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS
AR039059A1 (en) 2001-08-06 2005-02-09 Sanofi Aventis COMPOUND DERIVED FROM ACILAMINOTIAZOL, ITS USE, PROCEDURES TO PREPARE IT, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, AND INTERMEDIARY COMPOUNDS
EP2287152B1 (en) 2002-06-05 2015-01-14 Kaneka Corporation Process for producing optically active alpha-methylcysteine derivative
NZ584773A (en) 2004-09-17 2012-07-27 Whitehead Biomedical Inst Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity
US7449486B2 (en) 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
UA95907C2 (en) 2005-05-02 2011-09-26 Эррей Биофарма Инк. Mitotic kinesin inhibitors and methods of use thereof
EP1757290A1 (en) 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
WO2008042928A2 (en) 2006-10-03 2008-04-10 Array Biopharma, Inc. Oxadiazole and thiadiazole derivatives as mitotic kinesin inhibitors and methods of use thereof
ES2700613T3 (en) * 2008-07-16 2019-02-18 Bitop Ag Synthesis of cyclic amidines
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (en) 2010-04-23 2012-10-10 Cytokinetics Inc AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS
AR081331A1 (en) 2010-04-23 2012-08-08 Cytokinetics Inc AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME
EP2431035A1 (en) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
CN103435549A (en) * 2013-08-14 2013-12-11 无锡惠飞生物医药技术有限公司 5-methyl-7-amino-5H,7H-dibenzo[b,d]azepin-6-ketone preparation method
CN105646208B (en) * 2016-02-24 2018-10-16 潍坊晶润化工股份有限公司 The preparation method of methyl pyruvate

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0831920A4 (en) * 1995-06-06 2003-03-19 Athena Neurosciences Inc Novel cathepsin and methods and compositions for inhibition thereof

Also Published As

Publication number Publication date
YU7998A (en) 2002-06-19
CO4920244A1 (en) 2000-05-29
JP2001513107A (en) 2001-08-28
BR9807876A (en) 2000-02-29
IL130851A0 (en) 2001-01-28
AU6662298A (en) 1998-09-18
AR011164A1 (en) 2000-08-02
ZA981627B (en) 1999-10-05
ID22873A (en) 1999-12-16
HUP0001293A3 (en) 2000-09-28
NO994016D0 (en) 1999-08-19
HRP980093A2 (en) 1998-12-31
CN1253554A (en) 2000-05-17
HUP0001293A1 (en) 2000-08-28
EP0968198A1 (en) 2000-01-05
KR20000075767A (en) 2000-12-26
WO1998038177A1 (en) 1998-09-03
NO994016L (en) 1999-10-18
PL335424A1 (en) 2000-04-25
NZ336613A (en) 2001-10-26
PE59399A1 (en) 1999-06-21
EA199900778A1 (en) 2000-04-24
CA2278674A1 (en) 1998-09-03

Similar Documents

Publication Publication Date Title
TR199902071T2 (en) Heterocyclic compounds and their use in inhibition of β-amylioid peptide
TR199902938T2 (en) Compounds and methods that inhibit the release and/or synthesis of β-amyloid peptide.
TR199901343T2 (en) To inhibit the release and/or synthesis of β-amyloid peptide using cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions containing them, and such compounds. in methods.
TR199901128T2 (en) N-(aryl/heteroaryacetyl) amino acid esters, pharmaceutical compositions containing it, and the ability to inhibit β-amyloid peptide release and/or its synthesis using such compounds ntems.
BR9714358A (en) Derivatives of n- (aryl / heteroaryl) amino acid, pharmaceutical compositions comprising them, and methods for inhibiting the release of beta-amyloid peptide and / or its synthesis by using such compounds
TR200103469T2 (en) Prevention and treatment of amyloidogenic disease
BR0115427A (en) Compound, pharmaceutical composition, methods for inhibiting the release of beta-amyloid peptide and / or its synthesis, for treating Alzheimer's disease, and for preventing the disease and the progress of Alzheimer's disease, and, use of a compound.
NO20004803L (en) Smilagening and anzurogenin for the treatment of Alzheimer's disease
DK0695758T3 (en) Pentapeptidamides and esters for human cancer inhibition
BG101841A (en) Cellular adhesion inhibitors
ES2188584T3 (en) AMINA HETEROCICLICAL DERIVATIVES.
NO20045434L (en) A combination of an NMDA antagonist and acetylcholinesterase inhibitors for the treatment of Alzheimer's disease
ATE334668T1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISEASES
BG106586A (en) Pyrazolopyramidines as therapeutic agents
GB0025173D0 (en) Therapeutic agents
NZ237023A (en) 17beta-substituted-4-aza-5alpha-androstan-3-ones and pharmaceutical compositions
PL323490A1 (en) Tetralinic compounds exibiting acitity against multgiple-drug refractoriness
ATE147981T1 (en) ADMINISTRATION OF LAMOTRIGINE FOR THE TREATMENT OF NEURO-AIDS
TR200000455T2 (en) The use of fanquinone in the treatment of Alzheimer's disease.
NO20000519L (en) 2-acylaminopropanamines as tachykinin receptor antagonists
NO983177L (en) Use of the 1-enantiomer of centroman for the preparation of a pharmaceutical composition for the treatment or prophylaxis of breast cancer
MX9707642A (en) Pharmaceutical agents for the treatment of alzheimer's disease.
DK1147105T3 (en) Optically active pyridyl-4H-1,2,4-oxadiazine derivative and its use in the treatment of vascular disease
NO953072L (en) Use of inhibitors of ornithine aminotransferase for the manufacture of a medicament for the treatment of Alzheimer's disease
NO994339D0 (en) Use of <alfa> 1-acid glycoprotein in the preparation of a pharmaceutical composition